drugset
drugset / Trial / NCT05117138

Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

NCT05117138 ↗

Phase 1/2 Unknown 39 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer of the head and neck (HNSCC)，AMT-253 CAR-T cells in patients with moderate or far advanced melanoma.

Timeline

Start
2022-01-01
Primary completion
2023-12-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AMT-116 CAR-T cells Cell therapy — —
Subject AMT-253 CAR-T cells Cell therapy 1e+08 cells Intravenous

Indications

head and neck squamous cell carcinoma melanoma non-small cell lung carcinoma